AUPH:NSD-Aurinia Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 14.25

Change

0.00 (0.00)%

Market Cap

USD 1.79B

Volume

0.46M

Average Target Price

USD 33.50 (+135.09%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

N/A

USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

N/A

USD32.18B N/A N/A
MRNA Moderna, Inc

N/A

USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

N/A

USD24.87B N/A N/A
RPRX Royalty Pharma plc

N/A

USD24.33B 36.15 9.83
GMAB Genmab A/S

N/A

USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

N/A

USD19.73B N/A N/A
INCY Incyte Corporation

N/A

USD18.93B 47.64 35.20

ETFs Containing AUPH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -29.66% 29% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.66% 29% F 28% F
Trailing 12 Months  
Capital Gain 161.47% 88% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 161.47% 88% B+ 93% A
Trailing 5 Years  
Capital Gain 410.75% 92% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 410.75% 92% A- 94% A
Average Annual (5 Year Horizon)  
Capital Gain 65.27% N/A N/A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 65.27% N/A N/A 94% A
Risk Return Profile  
Volatility (Standard Deviation) 75.24% N/A N/A 13% F
Risk Adjusted Return 86.75% N/A N/A 89% B+
Market Capitalization 1.79B 84% B 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.76 29% F 19% F
Price / Cash Flow Ratio -28.21 86% B 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -77.60% 43% F 17% F
Return on Invested Capital -39.57% 73% C 22% F
Return on Assets -27.23% 50% F 14% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.64 53% F 45% F
Short Percent N/A N/A N/A N/A N/A
Beta 0.98 73% C 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector